High-throughput screening is an essential process in drug discovery. The ability to identify true active compounds depends on the high quality of assays and proper analysis of data. The Z factor, presented by Zhang et al. in 1999, provides an easy and useful summary of assay quality and has been a widely accepted standard. However, as data analysis has undergone much improvement recently, the assessment of assay quality has not evolved in parallel. In this article, the authors study the implications of Z factor values under different conditions and link the Z factor with the power of discovering true active compounds. They discuss the different interpretations of Z factor depending on error distributions and advocate direct analysis of power as assay quality assessment. They also propose that in estimating assay quality parameters, adjustments in data analysis should be taken into account. Studying the power of identifying true "hits" gives a more direct interpretation of assay quality and may provide guidance in assay optimization on some occasions. (Journal of Biomolecular Screening 2007:229-234) 
INTRODUCTION
H IGH-THROUGHPUT SCREENING (HTS) is an essential process in drug discovery and has been widely used in the pharmaceutical industry. Recently, with the advancement in technology, an increasing number of labs in academic settings have also started to miniaturize biological assays to adapt higher throughput. As scientists continue to improve the quality of HTS by technological developments, the importance of statistical data analysis has also gained greater acknowledgment. 1 The goal of HTS is to identify a small number of compounds with desired biological activity (true positives) among the vast majority of the "null" compounds that have no or little biological activity (true negatives) from large chemical libraries. In a successful assay, the compounds with biological activity produce signals with large differences from the mean of the library sample signals and appear as outliers. A cutoff is chosen so signals beyond the cutoff (greater than the cutoff for activation/ agonist assays and less than the cutoff for inhibition/antagonist assays) are declared "hits." Two types of inference errors can be made here. A true-negative compound can be falsely declared as a hit because of random noise. The probability of making falsepositive calls is referred to as the type I error rate. An active compound may fail to meet the cutoff, and the probability to make the false-negative error is referred to as type II error rate. The complementary probability (i.e., the probability of discovering active compounds as hits) is referred to as power.
An ideal assay is one that can reach a small false-positive rate and maintain a high power. For a given assay, one can always use a more stringent cutoff to reduce false positives, but at the same time, the power is also lowered. Thus, there is trade-off between minimizing the 2 types of errors. To limit the waste in follow-up experiments on the false hits, the conventional decision is to ensure a small false-positive rate by setting the cutoff to be 3 standard deviations (SDs) away from the sample mean. Assuming homogeneous variability of all "null" compounds and normality, this amounts to a 1-sided type I error (false positive) of .0013. However, some systematic variations in the measurement process can increase both false-positive and false-negative rates. For example, measurements on the edge of plates may be lower than measurements from the center. In an inhibition assay, null compounds on the edge will be more likely to become false hits. In an activation assay, active compounds on the edge may not be identified because their signal is reduced by the edge effect.
As a result of systematic variations, including positional effects and plate-to-plate variation, improved statistical methods have been proposed to adjust for these and to yield better hit selection procedures. 2,3 However, similar scrutiny has not been exercised in assay development and validation. Intuitively, an assay in which the distributions of sample signal and background are widely separated would be a good assay. The "separation" of 2 distributions depends on both the location and the scale of the distributions. Two summary statistics, the signal-to-noise ratio (S/N) and signal-to-background ratio (S/B), partially capture the information: S/N = (mean signal -mean background)/SD of background, and S/B = mean signal/mean background. However, both ratios fail to consider the variability of the sample and background (control) as well as the dynamic range of the assay at the same time. As a remedy, Zhang et al. 4 proposed a simple statistical parameter, Z factor, defined as (1) Z factor combines the information of both location and scale of the distributions of the sample signal and background and provides a better representation of the assay quality than S/B or S/N alone. Z factor takes values between -∞ and 1. Zhang et al. 4 gave guidance that for .5 ≤ Z < 1, there is good separation of the distributions, indicating an excellent assay; 0 < Z < .5 means moderate separation of the distributions and indicates a doable assay; Z = 0 means poor separation and a "yes/no"-type assay; and for Z < 0, screening is essentially impossible. In assay development, when sample signal data from the compound library are not available, positive controls and negative controls are used instead. A Z′ factor is similarly defined as (2) and can serve as a statistical parameter for the quality of the assay itself.
Since its introduction, the Z factor criterion has become the most widely used parameter in the evaluation and validation of HTS experiments. The publication of Zhang et al. 4 is one of the most cited papers in HTS. Large laboratories, including the National Institutes of Health Chemical Genomics Center (http://ncgc.nih.gov) and the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (http://nsrb.med.harvard.edu), recommend Z ≥ .5 as an indication of proper assay optimization. In a recent publication, Iversen et al. 5 conducted a simulation study and compared the performance of the Z factor to that of the signal window and assay variability ratio and recommended Z factor as a preferred assay performance measure.
There is no doubt about the usefulness and popularity of the Z factor. However, Z factor is developed under normal error distribution, and without careful check of error distributions, the use of Z factor can be misleading. In the following sections, we link the Z factor values to the power of identifying true active hits under different situations and advocate the analysis of power for evaluating HTS assays.
POWER INTERPRETATION OF Z FACTOR VALUES UNDER CONSTANT VARIANCE
A Z factor greater than .5 is often interpreted as an indication of acceptable assay quality, and Z < 0 is a sign of poor quality. Zhang et al. 4 did not give an explanation for why Z = .5 and 0 are critical values determining different categories of assay quality. Here we link the Z factors to power in the case of constant variance to illustrate the implications of these important Z factor values.
We will use an inhibition/antagonist assay as an example. The conclusion easily can be generalized to activation/agonist assays. Assume that the signal from null compounds with no biological activity follows normal distribution with mean µ s and standard deviation σ s , N(µ s , σ s ), and the negative control (background) data are distributed as N(µ c , σ c ). Following the terminology in Zhang et al., 4 we use negative control to refer to the controls that generate the minimum signal. In the case of constant variance, we have σ s = σ c = σ. Therefore,
We consider 2 types of true hits. The strongest possible inhibition would decrease the signal to the minimum signal level (i.e., the negative control). We define the reference power as the probability of declaring a compound as a hit if its signal is distributed as the negative controls. We also consider the 50% inhibition, meaning the signal is reduced halfway toward to negative control-that is, (µ s + µ c )/2. The 50% inhibition power is defined as the probability of declaring a compound as a hit if its mean signal is (µ s + µ c )/2. We choose 50% inhibition for illustration purposes. Other effect sizes may be of interest in practice depending on the application. We have made available computer code to reproduce the results in this article for other inhibition levels (http://stat.brown.edu/~ysui/Rcode/hts1.html).
Using the conventional hit limit of µ s -3σ, Table 1 summarizes the power for a few Z factor values. Under the common variance assumption, Z factor has a simple relationship with power. For Z > .5, the power of detecting compounds with larger than 50% inhibition is .999, indicating an excellent assay. When Z is only .25, the power is still higher than 80%. For Z = 0, the halfway power is only .5, meaning compounds with 50% inhibition will only be declared as hit or no hit with equal chances. Therefore, the "yes/no"-type assay 4 is a suitable term. The monotonic relationship between Z factor and power shows the agreement between the two in principle. The large power for even modest Z values suggests that the usual requirement of Z > .5 may be relaxed for assays with constant variance.
Z FACTOR AND POWER UNDER UNEQUAL VARIANCE
When the variance is constant among null compounds and hit compounds, the Z factor describes the ability of an assay to separate these two, regardless of the signal-to-noise ratio. Even for a Z factor as low as .1, there is considerable power (63%) in detecting compounds with at least 50% inhibition. However, when the variances are not equal, the link between Z factor and power is not so direct. In many assays, including immunoassays, the variance is not constant and is related to mean signal level. In these cases, standard deviation is often proportional to the mean-that is, the coefficient of variation (standard deviation/ mean) is constant.
Assuming normal distribution again and denoting the constant coefficient of variation with τ, we have that the signal from null compounds follows normal distribution N(µ s , µ s τ) and that the background follows N(µ c , µ c τ). Using the conventional hit limit, compounds with a signal less than µ s -3µ s τ will be declared hits in the inhibition assay. For a compound that reduces the signal to the level of negative control, the reference power P r is and the 50% inhibition power is Figure 1A illustrates the relationship between the S/B ratio and 50% inhibition power at different levels of the coefficient of variation (CV). Not surprisingly, for any given CV, power increases with the S/B ratio. But the benefit is minimal when CV is higher than 0.15 (i.e., the standard deviation is more than 15% of the average signal). For CV > .15, the 50% inhibition power is less than .75 even for an arbitrarily high S/B ratio.
The common cutoff of Z > .5, although not directly derived from power calculation, also supports a similar requirement on CV for an acceptable assay. Because the Z factor is directly linked to S/B and CV. The inequality also states that for CV larger than 1/6 (.17), the Z-factor will never reach .5. Therefore, powerless assays will not pass the quality control set by a Z factor greater than .5. Or equivalently, Z ≥ .5 is in general an indication of good power for 
common S/B ratios. In our examples, there is > 70% power for S/B ratios 5 and 10 when Z ≥ .5 ( Table 1) . However, depending on the CV, the exact power can be different for the same Z factor values. Figure 1B shows the relationship between Z factor and 50% inhibition power at different CV levels. For example, Z = .5 corresponds to power larger than .8 when CV = .1, but the power is only .6 when CV = .15. For ease of comparison with the constant-variance case, we computed the CV levels corresponding to Z factor values of .5, .1, and 0 under S/B ratios 10 and 5 in Table 1 . When S/B is 10, in order to reach Z = 0.5, the CV needs to be about .136. The 50% inhibition power is only about 0.7, although the same Z factor value means that the power is almost 1 when variance is constant. For a smaller CV of .111, the same Z = .5 can be obtained for S/B ratio 5, and 50% inhibition power is .84, similar to the power at Z = .25 under constant variance. Although under constant variance, one can relax the requirement of Z > .5 to Z > .25 or so and maintain considerable power, this is definitely not the case for constant CV situations. Blindly referring to cutoffs 0 or .5 without checking error distribution is not a proper use of the Z factor.
NORMAL ASSUMPTION AND DATA TRANSFORMATION
It should be noted that in the previous sections, we have assumed normal distributions for the power analysis. Although the calculation of Z factor is simple and does not reflect a distributional assumption, Z factor is developed under normal distribution, and it best reflects assay quality under normal distribution. Distributions deviating severely from normal could lead to fraudulent values. Figure 2 gives an example that naïve application of Z factor can be misleading. The same data are used in Figure 2A ,B except that the data are log transformed in Figure  2B . Data in original scale ( Fig. 2A) have a highly skewed distribution, and the log-transformed data (Fig. 2B) are approximately normal. The Z factor calculated from the raw data is -0.086, although Figure 2A shows good separation of the sample signal from background. The Z factor for the transformed data is .53. The striking difference in Z factor values would lead to opposite conclusions of assay quality: a reasonably good assay based on the transformed data and a useless assay if the Z factor is calculated from the untransformed data. Apparently, it is more appropriate to compute the Z factor in the log scale in this example.
Power calculations, relying on explicit distributional assumptions, certainly can suffer from misspecification of the distribution, too. Assuming normal distribution with constant CV for the data in Figure 2A leads to estimated 50% inhibition power close to 0. The small estimated power is largely due to invalid normal assumption of the highly skewed data. Also, the hit limit µ s -3σ s is no longer a reasonable cutoff for identifying hits with inhibition property when the sample signal is right skewed. After log transformation, the distributions of sample signal and background both appear to be normal, and the variances are close. The estimated 50% inhibition power under the equal-variance normal distribution assumption is close to 1. This is in agreement with the clear separation of sample signal and background in Figure 2B . It should be noted that a 50% decrease in transformed scale has a different interpretation from a 50% decrease in original scale. Power should be calculated with an effect size that is scientifically meaningful. Therefore, one may need to consider a different effect size when data transformation is necessary. In many biochemistry assays using unbiased chemical libraries, the distribution of signal from null compounds is well approximated with a normal distribution. The conventional hit limit (i.e., 3 SDs from the sample signal mean as cutoff) corresponds to a 1-sided type I error (false-positive) rate less than .0014. However, the normal distribution assumption is not always valid, especially in cell-based assays, and data transformation may be necessary. Although, unlike power calculation, the formula for Z factor calculation does not reflect distributional assumption, we emphasize that Z factors are most useful under normal distribution. Calculating the Z factor and comparing it to absolute critical values such as .5 and 0 in assay quality assessment can lead to wrong conclusions if the Z factor is not computed on an appropriate scale.
DISCUSSION AND RECOMMENDATIONS
Whether we are assessing the quality of a given plate or the quality of an assay itself in assay development and validation, the goal is to ensure an acceptable low false-positive rate and falsenegative rate in the hit selection procedure. Therefore, we strongly recommend directly looking at power and the falsepositive rate for assessing assay quality and using the Z factor with caution. As in the definition of the Z′ factor, if we replace the µ s with positive control µ c+ , we can estimate power for the assay using control data only and use it as guidance for assay development and optimization. In our examples and results presented in previous sections, we have chosen 50% inhibition and the conventional cutoff for hit identification for illustration purposes. In practice, the relevant effect size varies from case to case, and a different hit limit may be used to control false positives. The most useful power analysis is carried out with the effect size meaningful to scientific applications, and the relationship between Z factor and power may change accordingly.
Power calculation requires specification of a probability distribution. In our examples, we have used normal distribution. In practice, the error distribution is never known, and the calculation based on normal distribution is only an approximation. In some cases, data have to be transformed to be at least approximately normal. The relationship between mean and variance also affects power calculation. The above limitation partially explains why power calculation is not yet widely used in HTS assays. On the contrary, the Z factor is simple to compute and does not have an explicit distributional assumption. Our examples show that in many cases, Z factor qualitatively agrees with power. However, the implication of the Z factor on false-positive and false-negative rates (i.e., "how large is large enough" for the Z factor) may depend on the relationship between mean and variance, as well as the signal-to-background ratio. Although the calculation of the Z factor does not require distributional assumption, it is most useful when the data are approximately normal. Therefore, for the use of Z factors, we also recommend checking error distributions. The same Z factor value corresponds to different power under different error distributions. Thus, the interpretation of Z factor is not clear without specifying the probability distributions, which is also required for power calculation. In practice, one should always check the empirical distribution of the sample signal and controls to validate the distributional assumption. Data transformation may be necessary to satisfy the normality assumption, or a different parametric distribution should be used to calculate power. The calculation of power and the Z factor should both take into account the analysis method for hit selection. For example, computing power or the Z factor requires the estimates of mean and standard deviation, both sensitive to outliers. One true hit compound that has a strong inhibition effect in an antagonist assay may have a signal much lower than the rest of the compounds. As a result, it decreases the mean and inflates the SD estimates, resulting in a smaller Z factor and lower power estimate compared to a similar assay without such a hit. This sensitivity to outliers certainly is not desirable. Robust estimates of mean and SD, such as median and scaled median absolute deviation, have been proposed in the hit selection process 1,2 and should also be used in assay quality assessment. Another example of current inconsistency between analysis and quality control is the adjustment for positional effects. Without adjusting for positional effects, mean estimates are biased, and SD estimates are higher and result in poor assay quality measures. Cell-based assays often suffer from edge effects and can have an unacceptably high plate rejection rate. 6 However, a simple statistical method such as median polish has proven useful in adjusting for edge effects. Therefore, a plate with large variance due to the edge effect may no longer be a bad assay when we have the analysis tool to adjust for it. When the hit selection procedure includes adjustment for edge effects, the assay quality measure should also be calculated with the adjustment. Thus, in addition to improving the experimental technique, as Lundholt et al. 6 did, an assay quality measure calculated in consistency with the hit selection method will also reduce the plate rejection rate.
Many factors in HTS assay can affect the error distribution and hence the assay quality. It is impractical to test all possible combinations of buffer types, concentration, incubation temperature, and other factors to find an optimal assay. However, different factors may affect different stochastic properties. For example, in cell-based assays, cell proliferation may affect the coefficient of variation more, and incubation time may have a stronger effect on the signal-to-background ratio. Under constant coefficient of variation, Figure 1A suggests that if the CV is small, increasing signal-to-background ratio will greatly increase the power. If the CV is larger than .15, it is better to focus on reducing the CV first.
In our examples, we have focused on power analysis of 50% inhibition with a fixed hit limit, µ s -3 SD. (For activation-type assays, considering 100% activation gives a similar result.) Ideally, one would like to consider the costs of following up false positives (type I error) and missing true positives (type II error) and make a decision of hit selection by minimizing the loss function, combining the 2 types of error. In practice, it is hard to quantify the costs, and the errors are considered separately. Nonetheless, one may choose to consider several hit limits or different inhibition/activation effects in the assay development. The estimated error rates will change according to these choices, but the same relationship among error rates, Z factor, and signal distributions mentioned above still applies.
